Medical cannabis producer INDIVA is growing like, well, a weed
The London-based medical grade cannabis producer is looking to expand production
London's only medical grade cannabis producer, INDIVA has announced plans to expand, adding 30,000 square feet of space and dozens of jobs to its current 10,000 square foot growing and production facility.
The announcement was made at an open house Wednesday at the company's high security facility in London's south-end.
"We're in for a lot of growth, no puns intended," INDIVA co-founder, president and CEO Neil Marrotta said Wednesday. "We're up to 25 employees now, I think we'll get close to 50 by the end of the year."
Marrotta said that INDIVA would also increase its production.
The company is working on a number of new products, including cannabidiol salt and sugar, which could give seasonings the same analgesic, anti-inflammatory and anti-anxiety properties that medical grade cannabis provides.
Marrotta said the company is also working on a line of recreational marijuana products, which will be launched once the law allows.
"We still can't quite yet sell recreationally, the law isn't officially passed," he said. "It hasn't achieved royal assent. We're very close to that and we embrace the recreational market and will provide the same high quality products, whether you're a patient or a customer."
Today the federal government rejected several changes made by the Senate to the cannabis legalization bill, setting a potential showdown between the upper chamber and the House of Commons.
The Senate has proposed 46 amendments to The Cannabis Act, and while the government is accepting some of them, it is passing on several major ones.
Those include affirming the provinces' right to ban home grown marijuana, banning branded promotional items, such as t-shirts and hats that display the logos of marijuana producers and establishing a public registry of all cannabis companies' directors, staff, as well as controlling corporations or trusts.